A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

Summary

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

Timeline

Start

2015-08

Primary completion

2016-11

Completion

2017-08-03

Outcome

Met primary endpoint

registry analysis (superiority test); 80 mg Ixekizumab Q4W vs 80 mg Ixekizumab Q2W; p =0.005; Risk Difference (RD) 7.9; Regression, Logistic NCT02513550 ↗

registry analysis (superiority test); 80 mg Ixekizumab Q4W vs 80 mg Ixekizumab Q2W; p =0.006; Risk Difference (RD) 6.9; Regression, Logistic NCT02513550 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ixekizumab	Monoclonal antibody	80 mg	Subcutaneous

Indications